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In a recent paper in Cell, Dreses-Wer-
ringloer et al. (2008) reported the identi-
fication and functional characterization 
of a new Alzheimer’s disease (AD) gene, 
CALHM1, encoding calcium homeostasis 
modulator 1. CALHM1 (formerly anno-
tated as FAM26C) represents a compel-
ling candidate gene for late-onset AD as 
it is located on chromosome 10q24, a 
consistently replicated AD linkage region 
(Bertram et al., 2007), is highly expressed 
in the hippocampus, which is severely 
affected by AD-related pathology, and 
is involved in calcium ion homeostasis, 
which may be disrupted in AD. In view of 
these converging leads, Dreses-Werrin-
gloer et al. (2008) sequenced the open 
reading frame of CALHM1 in a small sam-
ple of AD patients and healthy controls 
and identified a nonsynonymous poly-
morphism (Pro86Leu, rs2986017) whose 
minor leucine allele showed a higher 
frequency in the AD patients. Followup 
analyses in four additional independent 
samples of ~3400 DNAs revealed a con-
sistent overrepresentation of the same 
allele in AD cases compared to controls in 
each dataset. From the combined analy-
ses the authors estimated that inheritance 
of the leucine allele modestly, but signifi-
cantly, elevated the risk for AD by ~40% 
(p value = 2 × 10−10). Their genetics find-
ings were supported by data generated 
in a large number of functional genomics 
and biochemical experiments showing 
evidence that the risk-associated leucine 
allele leads to a loss of protein function, 
including attenuated permeability to cal-
cium ions and reduced cytosolic calcium 
ion levels, which, in turn, were associated 
with an increase in the pathogenic pep-
tide, amyloid-β (Aβ). Here, we present an 
independent assessment of the potential 
association between AD and the Pro-
86Leu single-nucleotide polymorphism 
(SNP) in CALHM1 in more than 8100 
subjects from several independent data-
sets comprised of AD families—including 
those in which the original chromosome 
10q24 linkage signal was identified (Ber-tram et al., 2000)—as well as unrelated 
cases and controls, and we find no evi-
dence of a genetic association in these 
samples.
The family-based datasets (CAG, NIA, 
NIMH, NCRAD) tested in this project are 
of self-reported European (Caucasian) 
ancestry collected in the US for the study 
of genetic factors in AD (see Table S1, 
available online, for a summary of sample 
characteristics). All samples were primarily 
sibships and lacked parental genotypes. 
With the exception of the CAG sample, the 
majority of pedigrees analyzed here were 
nuclear families ascertained on the basis 
of multiple affected individuals. In addition 
to containing at least one affected relative 
pair, many pedigrees also had DNA avail-
able from additional affected or unaffected 
individuals (mostly siblings). The diagno-
sis of definite, probable, or possible AD 
was made according to NINCDS/ADRDA 
criteria for affected individuals in all four 
samples (McKhann et al., 1984). In addi-
tion to the family samples, we genotyped 
~1300 unrelated AD cases and controls, 
which were collected at two sites in North-
ern Europe, Sweden, and Finland (Table 
S1). All subjects were Caucasian, and AD 
patients fulfilled NINCDS/ADRDA criteria 
for probable AD. The Swedish AD patients 
were ascertained at the Memory Disor-
der Unit at Uppsala University Hospital. 
Healthy control subjects were recruited 
from the same geographic region following 
advertisements in local newspapers and 
displayed no signs of dementia upon neu-
ropsychological testing. The Finnish sub-
jects were gathered from Eastern Finland 
and were examined in the Department of 
Neurology of Kuopio University Hospital. 
Control subjects had no signs of demen-
tia following neuropsychological testing. 
Finally, we assessed the CALHM1 locus 
in two previously published high-density 
genome-wide association studies (GWAS) 
(Li et al., 2008; Reiman et al., 2007) for 
which genotype data are publicly available. 
Together, these studies investigated 2900 
unrelated AD cases and controls. Given Cell 135, Dthat the rs2986017 (Pro86Leu) variant was 
not tested directly in either of the GWAS, 
we tested two SNPs showing strong and 
significant linkage disequilibrium with the 
rs2986017 (Pro86Leu) variant (rs2986030 
[D’ = 0.89, r2 = 0.71] and rs1555823 [D’ = 
0.89, r2 = 0.64]). Note that the power to 
detect the effect sizes described in the 
original report (Dreses-Werringloer et al., 
2008) was still very high (>90%) due to 
the strong linkage disequilibrium between 
these variants (Table S2).
Genotyping of the rs2986017 (Pro86Leu) 
variant in the US family samples and the 
Northern European case-control datasets 
was based on an individually optimized 
single-base extension reaction detected 
by high-efficiency fluorescent polarization 
(HEFP; described in Bertram et al., 2005; 
protocols available on request). Overall, 
genotyping efficiency was 97.6%, and 
the average error rate was below 0.2%. 
Resequencing of the Pro86Leu variant 
in 20 individuals revealed 100% concor-
dance with the HEFP genotype results. 
None of the markers deviated significantly 
from Hardy-Weinberg equilibrium. To test 
for association with AD risk in the family-
based samples we used PBAT (http://
www.biostat.harvard.edu/~clange/default.
htm) applying an additive model. Odds 
ratios (ORs) for the family samples were 
calculated by fitting a conditional logistic 
regression model to each dataset, where 
family defines the stratum. To test for 
association in the case-control samples 
(including the markers extracted from the 
GWAS) we calculated allele-based study-
specific crude ORs, 95% confidence inter-
vals, and p values for each marker (Ber-
tram et al., 2007). To combine the effect 
size estimates obtained in this study with 
those estimated in the original publication, 
summary ORs across all samples were 
calculated using the DerSimonian and 
Laird random effects model, in line with 
the analyses routinely performed for the 
AlzGene database (Bertram et al., 2007). 
Power calculations (performed in PBAT) 
suggested that we had sufficient (i.e., 70% 
or greater) power to detect the genetic 
effect size estimated in the original study 
in each of the samples, with the exception 
of the CAG dataset (Table S2).
As shown in Figure S1 and Table S2, 
none of the eight samples we investigated 
showed evidence for significant associa-
tion between the rs2986017 (Pro86Leu) ecember 12, 2008 ©2008 Elsevier Inc. 993
variant in CALHM1 and AD risk (p values 
ranging from 0.15 to 0.84). Stratification by 
age of AD onset (using 65 years as cutoff) 
or APOE ε4-genotype did not apprecia-
bly change these results (data not shown; 
stratified analyses were not possible in 
the GWAS samples as no onset age or 
APOE ε4 data were supplied). Effect size 
estimates indicated insignificant ORs 
that were opposite in direction to those 
reported by Dreses-Werringloer et al. 
(2008) in six of the eight samples (see Fig-
ure S1). Accordingly, summary ORs calcu-
lated across the newly genotyped samples 
in our study (labeled “This study” in Figure 
S1) were insignificant (OR = 0.94 [95% CI: 
0.83–1.07], p = 0.4) and tended toward 
null when combined with the published 
GWAS genotype data (“All follow-up”; OR 
= 0.99 [95% CI: 0.91–1.09], p = 0.9). Upon 
combining these data with the results of 
the original study (“All studies”), that is, 
generating a meta-analysis on all ~11,700 
currently available subjects, the overall 
summary OR became insignificant as well 
(OR = 1.13 [95% CI: 0.99–1.27], p = 0.06). 
Using rs1555823 (instead of rs2986030) as 
proxy for the rs2986017 (Pro86Leu) variant 
in the GWAS samples revealed even less 
pronounced and less significant overall 
effects (data not shown).
Thus, we have independently assessed 
the potential association between AD risk 
and the rs2986017 (Pro86Leu) variant in the 
CALHM1 gene in a large number of inde-
pendent datasets, including AD families 994 Cell 135, December 12, 2008 ©2008 Els
We recently reported the association of the 
CALHM1 gene with late-onset Alzheimer’s 
disease (LOAD) risk in four independent 
populations of more than 3000 partici-
pants (Dreses-Werringloer et al., 2008). 
We showed that the rare allele of the non-
synonymous SNP rs2986017 in CALHM1 
increases LOAD risk by about 40% (p = 
Response 
CALHM1 Assoc
Alzheimer’s Disin which the original chromosome 10q24 
linkage signal was identified (Bertram et 
al., 2000). Despite good to excellent power 
to detect genetic effect sizes on the order 
described by Dreses-Werringloer et al. 
(2008), no association between CALHM1 
and AD was observed, either in the indi-
vidual samples or in the combined analy-
ses of more than 8100 subjects. Based 
on these negative data, it is doubtful that 
CALHM1 represents more than a minor 
genetic determinant of AD risk.
Supplemental Data
Supplemental Data include two tables and one figure 
and can be found with this article online at http://www.
cell.com/supplemental/S0092-8674(08)01505-5.
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2 × 10−10). Importantly, we also demon-
strated the functional significance of the 
CALHM1 rs2986017 SNP by showing that 
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phism increased levels of the pathogenic 
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(2007). Neuron 54, 713–720.tion between LOAD risk and CALHM1 and 
report an inability to replicate the associa-
tion in more than 5000 individuals. Here, 
we comment on several important meth-
odological points in the study of Bertram 
et al., and we present new evidence that 
supports the association of CALHM1 with 
both LOAD risk and age of AD onset.
Family-Based Association Studies
The main contribution of the Bertram et al. 
study lies in the analysis of the CALHM1 
rs2986017 SNP on LOAD risk in four inde-
pendent family-based populations. The 
authors observed no significant genetic 
association. They combined these family-
